Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Lundbeck
  6. News
  7. Summary
    LUN   DK0061804697

LUNDBECK

(LUN)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-09-30 am EDT
22.65 DKK   +0.69%
09/13Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults
CI
08/17Transcript : H. Lundbeck A/S, Q2 2022 Earnings Call, Aug 17, 2022
CI
08/17Lundbeck's sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the first half of 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

06/27/2022 EDT

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced positive results of the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia (NCT03548584). The analysis concluded that there is a statistically significant difference (p=0.0026) in the mean change from baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score between brexpiprazole and placebo. Full study results are not yet available.

Further prespecified and exploratory analyses of the data set will be conducted to determine the full potential of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia. Based on this outcome Lundbeck and Otsuka are planning a regulatory filing to the FDA later in 2022. The Supplemental New Drug Application will be comprised of this study as well as two earlier trials.

In February 2016, the FDA granted fast track designation for brexpiprazole for treatment of agitation in patients with Alzheimer's dementia. Lundbeck and Otsuka are incredibly grateful to all the patients with Alzheimer´s dementia, their families, caregivers, and the investigators who participated in the trials and contributed greatly to this research. The trial results are planned to be submitted for scientific publication at a later date.

Trial 331-14-213 (NCT03548584; Trial 213) was designed to assess the safety, tolerability and efficacy of two fixed doses of brexpiprazole (2 mg/day and 3 mg/day) in the treatment of patients with agitation in Alzheimer's dementia. The trial consisted of a continuous 12-week double-blind treatment period with a 30-day follow-up. The randomized trial population included 345 male and female patients, aged 55-90 years (inclusive), with a diagnosis of probable Alzheimer's disease, and meeting criteria of agitation as defined by the International Psychogeriatric Association (IPA).

The primary outcome was the change in the CMAI total score at week 12 for all patients treated with brexpiprazole versus those treated with placebo. The key secondary outcome was the change in the Clinical Global Impression - Severity of Illness (CGI-S) score, as related to symptoms of agitation. Participating countries include Bulgaria, Hungary, Serbia, Slovakia, Spain, Ukraine, and USA.

The study included both patients who were living at home and those living in institutionalized settings. In the study, the improvements from baseline on the primary endpoint of CMAI for patients receiving brexpiprazole or 2 mg/day or 3 mg/day were statistically greater than for those receiving placebo (p=0.0026). This result was supported by a statistically superior improvement on the key secondary endpoint of CGI-S, as related to agitation (p=0.0055).

Brexpiprazole was generally well tolerated, and no new safety signals were observed. The only Treatment Emergent Adverse Event (TEAE) with more than 5% incidence in patients treated with brexpiprazole was headache (6.6% vs. 6.9% for placebo).

The following TEAEs occurred at an incidence of at least 2% in brexpiprazole treatment group and greater than that of placebo: somnolence, nasopharyngitis, dizziness, diarrhea, urinary tract infection, and asthenia. There was one death observed in the 3 mg/day treatment group, assessed as not related to treatment by the investigator.


ę S&P Capital IQ 2022
All news about LUNDBECK
09/13Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazo..
CI
08/17Transcript : H. Lundbeck A/S, Q2 2022 Earnings Call, Aug 17, 2022
CI
08/17Lundbeck's sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the..
AQ
08/17H. Lundbeck A/S Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
CI
08/17H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022
CI
08/09Lundbeck raises financial guidance range for the full year 2022
AQ
08/09H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022
CI
07/26Lundbeck : Conducting largest study ever to observe early-stage multiple system atrophy
PU
07/13Lundbeck A/S - Transactions with shares and linked securities in H. Lundbeck A/S made b..
AQ
07/12Transactions with shares and linked securities in H. Lundbeck A/S made by executives an..
AQ
More news
Financials
Sales 2022 17 696 M 2 332 M 2 332 M
Net income 2022 1 616 M 213 M 213 M
Net Debt 2022 2 340 M 308 M 308 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 23 809 M 3 137 M 3 137 M
EV / Sales 2022 1,48x
EV / Sales 2023 1,18x
Nbr of Employees 5 437
Free-Float 99,9%
Chart LUNDBECK
Duration : Period :
Lundbeck Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUNDBECK
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 22,65 DKK
Average target price 190,00 DKK
Spread / Average Target 739%
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
J÷rg Hornstein Chief Financial Officer
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
LUNDBECK-33.40%3 137
JOHNSON & JOHNSON-4.51%432 579
ELI LILLY AND COMPANY19.47%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.89%247 841